The Cochrane Oral Health Group's Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), Medline and Embase databases were searched with no language or date restrictions. Two ...
PROPEL (Intersect ENT) sinus implants are designed to keep the sinus open and deliver steroids directly to the sinus mucosa after sinus surgery. It's made of a synthetic bioabsorbable co-polymer with ...
Intersect ENT is launching its Sinuva Sinus Implant, a new approach to treating nasal polyp disease in adult patients who have had previous sinus surgery. The Menlo Park, CA-based company said nearly ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT ®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U ...
Lower health care utilization was shown in patients with chronic rhinosinusitis, with and without nasal polyps, who had steroid-eluting implants vs those who did not in the 18 months following ...
MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results